Immunotherapy for Infectious Diseases

196 Kalams
virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med
1991; 324:1677.
108. Sitz KV, Ratto-Kim S, Hodgkins AS, Robb ML, Birx DL. Proliferative responses to
human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals
immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected
controls. J Infect Dis 1999; 179:817.
109. Ratto-Kim S, Sitz KV, Garner RP, et al. Repeated immunization with recombinant gp160
human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation
of the T cell proliferative response. J Infect Dis 1999; 179:337.
110. Schooley RT, Spino C, Kuritzkes D, et al. Two double-blinded, randomized, comparative
trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1infected
individuals across a spectrum of disease severity: AIDS Clinical Trials Groups
209 and 214. J Infect Dis 2000; 182:1357.
111. Birx DL, Loomis-Price LD, Aronson N, et al. Efficacy testing of recombinant human
immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1infected
volunteers. rgp160 Phase II Vaccine Investigators. J Infect Dis 2000; 181:881.
112. Sattentau QJ, Moore JP. Human immunodeficiency virus type 1 neutralization is determined
by epitope exposure on the gp120 oligomer. J Exp Med 1995; 182:185.
113. Moore JP, Sodroski J. Antibody cross-competition analysis of the human immunodeficiency
virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996; 70:1863.
114. Trauger RJ, Ferre F, Daigle AE, et al. Effect of immunization with inactivated gp120depleted
human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity,
viral DNA, and percentage of CD4 cells. J Infect Dis 1994; 169:1256.
115. Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ. 1995. Safety
and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind,
adjuvant controlled trial. J Acquir Immun Defic Syndr 1995; 10 (Suppl 2):S74.
116. Moss RB, Giermakowska W, Wallace MR, Savary J, Jensen F, Carlo DJ. T-helper-cell
proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and
p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen
(Remune). Clin Diagn Lab Immunol 2000; 7:724.
117. Pontesilli O, Carotenuto P, Kerkhof-Garde SR, et al. Lymphoproliferative response to HIV
type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDSfree
infection. AIDS Res Hum Retroviruses 1999; 15:973.
118. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen,
an immunologic modifier, administered to patients infected with HIV having 300 to 549
� 10(6)/L CD4 cell counts: a randomized controlled trial. JAMA 2000; 284:2193.
119. Egan MA, Pavlat WA, Tartaglia J, et al. Induction of human immunodeficiency virus type
1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating,
host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.
J Infect Dis 1995; 171:1623.
120. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human
immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120,
HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine
Evaluation Group. J Infect Dis 1998; 177:1230.
121. Ferrari G, Berend C, Ottinger J, et al. Replication-defective canarypox (ALVAC) vectors
effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present
in infected patients: implications for antigen-specific immunotherapy. Blood 1997;
90:2406.
122. Evans TG, Keefer MC, Weinhold KJ, et al. A canarypox vaccine expressing multiple
human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and
durable CD8� cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis
1999; 180:290.